Baker BROS. Advisors LP Buys New Position in BioCryst Pharmaceuticals, Inc. $BCRX

Baker BROS. Advisors LP bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the fourth quarter, Holdings Channel.com reports. The fund bought 2,822,727 shares of the biotechnology company’s stock, valued at approximately $22,017,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BCRX. RA Capital Management L.P. acquired a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at approximately $123,452,000. Deerfield Management Company L.P. grew its holdings in BioCryst Pharmaceuticals by 159.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after buying an additional 7,477,000 shares during the last quarter. Qube Research & Technologies Ltd grew its holdings in BioCryst Pharmaceuticals by 152.3% in the 2nd quarter. Qube Research & Technologies Ltd now owns 2,373,489 shares of the biotechnology company’s stock valued at $21,266,000 after buying an additional 1,432,824 shares during the last quarter. Bank of America Corp DE grew its holdings in BioCryst Pharmaceuticals by 97.9% in the 2nd quarter. Bank of America Corp DE now owns 2,841,155 shares of the biotechnology company’s stock valued at $25,457,000 after buying an additional 1,405,498 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at approximately $10,580,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock opened at $8.95 on Thursday. The stock’s fifty day simple moving average is $8.92 and its 200 day simple moving average is $8.16. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of -5.03 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $10.32.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The firm had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. During the same quarter last year, the firm posted $0.20 EPS. The business’s revenue was up 7.5% on a year-over-year basis. On average, research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on BCRX shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Wedbush cut their price objective on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Evercore began coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price objective for the company. Citizens Jmp upped their price objective on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, May 7th. Finally, Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $20.70.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.